Use of ketogenic diets in the treatment of central nervous system diseases: a systematic review
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Use of ketogenic diets in the treatment of central nervous system diseases : a systematic review. / Christensen, Magnus G.; Damsgaard, Jakob; Fink-Jensen, Anders.
I: Nordic Journal of Psychiatry, Bind 75, Nr. 1, 2021, s. 1-8.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Use of ketogenic diets in the treatment of central nervous system diseases
T2 - a systematic review
AU - Christensen, Magnus G.
AU - Damsgaard, Jakob
AU - Fink-Jensen, Anders
N1 - Publisher Copyright: © 2020 The Nordic Psychiatric Association.
PY - 2021
Y1 - 2021
N2 - Background: Studies have consistently shown that patients with epilepsy could benefit from ketogenic diets (KDs). Recent evidence suggests that KD could be used in the treatment of central nervous system (CNS) diseases. The aim of this systematic review was to investigate the use and efficacy of KD, modified Atkins diet (MAD) and medium-chain triglyceride (MCT) diet in infants, children, adolescents, and adults with CNS diseases. Methods: This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Main databases, i.e. EMBASE, PubMed and PsycINFO, were searched on 4 December 2019. Only randomized clinical trials (RCTs) were included and only if they reported KD, MCT or MAD interventions on patients with CNS diseases. Results: Twenty-four publications were eligible for inclusion (n = 1221). Twenty-one publications concerned epilepsy, two concerned Alzheimer’s disease (AD), and one concerned Parkinson’s disease (PD). All studies regarding epilepsy reported of seizure reduction compared to baseline. MCT did not significantly change regional cerebral blood flow (rCBF) in patients with AD, but MAD significantly improved memory at 6 weeks (p =.03). KD significantly improved motor and nonmotor functions in patients with PD at 8 weeks (p <.001). There was a trend towards fewer adverse effects in MAD compared to KD. Conclusion: In conclusion, various forms of KDs seem tolerable and effective as part of the treatment for epilepsy, AD and PD, although more investigation concerning the mechanism, efficacy and adverse events is necessary.
AB - Background: Studies have consistently shown that patients with epilepsy could benefit from ketogenic diets (KDs). Recent evidence suggests that KD could be used in the treatment of central nervous system (CNS) diseases. The aim of this systematic review was to investigate the use and efficacy of KD, modified Atkins diet (MAD) and medium-chain triglyceride (MCT) diet in infants, children, adolescents, and adults with CNS diseases. Methods: This systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Main databases, i.e. EMBASE, PubMed and PsycINFO, were searched on 4 December 2019. Only randomized clinical trials (RCTs) were included and only if they reported KD, MCT or MAD interventions on patients with CNS diseases. Results: Twenty-four publications were eligible for inclusion (n = 1221). Twenty-one publications concerned epilepsy, two concerned Alzheimer’s disease (AD), and one concerned Parkinson’s disease (PD). All studies regarding epilepsy reported of seizure reduction compared to baseline. MCT did not significantly change regional cerebral blood flow (rCBF) in patients with AD, but MAD significantly improved memory at 6 weeks (p =.03). KD significantly improved motor and nonmotor functions in patients with PD at 8 weeks (p <.001). There was a trend towards fewer adverse effects in MAD compared to KD. Conclusion: In conclusion, various forms of KDs seem tolerable and effective as part of the treatment for epilepsy, AD and PD, although more investigation concerning the mechanism, efficacy and adverse events is necessary.
KW - central nervous system disease
KW - Ketogenic diet
KW - medium-chain triglyceride diet
KW - modified Atkins diet
U2 - 10.1080/08039488.2020.1795924
DO - 10.1080/08039488.2020.1795924
M3 - Review
C2 - 32757903
AN - SCOPUS:85089065103
VL - 75
SP - 1
EP - 8
JO - Nordisk Psykiatrisk Tidsskrift
JF - Nordisk Psykiatrisk Tidsskrift
SN - 0803-9496
IS - 1
ER -
ID: 269601096